Telix Joins Thera4Care with TLX400-Tx to Accelerate Translation of Next Generation FAP-Targeting Theranostics
Telix is joining the Thera4Care initiative to help develop next-generation theranostics. The goal of the initiative is to create an integrated ecosystem for better patient access in Europe. Telix's candidate TLX400-Tx targets fibroblast activation protein. This candidate was chosen for evaluation using terbium-161 based on scientific interest and clinical potential. Data from this work will guide future development.
Thera4Care is an initiative aimed at establishing an integrated theranostics ecosystem to broaden patient access in Europe Telix’s fibroblast activation protein (FAP) targeting therapy candidate (TLX400-Tx) has been selected for evaluation with terbium-161 based on clinical potential and external scientific interest Data generated through the collaboration are expected to help inform future development directions for […]